Continuous Ultrafiltration in Acute Decompensated Heart Failure: Current Issues and Future Directions

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Most patients hospitalized for acutely decompensated heart failure (ADHF) present with symptoms and signs of volume overload, which are also associated with high rates of death and re-hospitalization. Several studies have investigated the possible use of extracorporeal ultrafiltration in the management of ADHF, evaluating potential clinical benefits in terms of hospitalization and survival rates versus those of conventional diuretic therapy. Though ultrafiltration remains an extremely appealing therapeutic option for patients with AHDF, some of the most recent studies have reported conflicting results. Differences in the selection of study population, heterogeneity of the indications for the use of ultrafiltration, disparity in the ultrafiltration protocols, and high variability in the pharmacologic therapies used for the control group could explain some of these contradictory findings. The purpose of the present review is to provide an overview and an update on the mechanisms and clinical effects of ultrafiltration and on currently available evidence supporting its use in ADHF.

Original languageEnglish
Pages (from-to)103-112
Number of pages10
JournalAmerican Journal of Cardiovascular Drugs
Volume15
Issue number2
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Ultrafiltration
Heart Failure
Hospitalization
Population Characteristics
Diuretics
Signs and Symptoms
Therapeutics
Survival Rate
Direction compound
Control Groups
Mortality

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

@article{653d8642e4cd40fcbfbba811c122970a,
title = "Continuous Ultrafiltration in Acute Decompensated Heart Failure: Current Issues and Future Directions",
abstract = "Most patients hospitalized for acutely decompensated heart failure (ADHF) present with symptoms and signs of volume overload, which are also associated with high rates of death and re-hospitalization. Several studies have investigated the possible use of extracorporeal ultrafiltration in the management of ADHF, evaluating potential clinical benefits in terms of hospitalization and survival rates versus those of conventional diuretic therapy. Though ultrafiltration remains an extremely appealing therapeutic option for patients with AHDF, some of the most recent studies have reported conflicting results. Differences in the selection of study population, heterogeneity of the indications for the use of ultrafiltration, disparity in the ultrafiltration protocols, and high variability in the pharmacologic therapies used for the control group could explain some of these contradictory findings. The purpose of the present review is to provide an overview and an update on the mechanisms and clinical effects of ultrafiltration and on currently available evidence supporting its use in ADHF.",
author = "Giancarlo Marenzi and Marco Morpurgo and Piergiuseppe Agostoni",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s40256-015-0107-6",
language = "English",
volume = "15",
pages = "103--112",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Continuous Ultrafiltration in Acute Decompensated Heart Failure

T2 - Current Issues and Future Directions

AU - Marenzi, Giancarlo

AU - Morpurgo, Marco

AU - Agostoni, Piergiuseppe

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Most patients hospitalized for acutely decompensated heart failure (ADHF) present with symptoms and signs of volume overload, which are also associated with high rates of death and re-hospitalization. Several studies have investigated the possible use of extracorporeal ultrafiltration in the management of ADHF, evaluating potential clinical benefits in terms of hospitalization and survival rates versus those of conventional diuretic therapy. Though ultrafiltration remains an extremely appealing therapeutic option for patients with AHDF, some of the most recent studies have reported conflicting results. Differences in the selection of study population, heterogeneity of the indications for the use of ultrafiltration, disparity in the ultrafiltration protocols, and high variability in the pharmacologic therapies used for the control group could explain some of these contradictory findings. The purpose of the present review is to provide an overview and an update on the mechanisms and clinical effects of ultrafiltration and on currently available evidence supporting its use in ADHF.

AB - Most patients hospitalized for acutely decompensated heart failure (ADHF) present with symptoms and signs of volume overload, which are also associated with high rates of death and re-hospitalization. Several studies have investigated the possible use of extracorporeal ultrafiltration in the management of ADHF, evaluating potential clinical benefits in terms of hospitalization and survival rates versus those of conventional diuretic therapy. Though ultrafiltration remains an extremely appealing therapeutic option for patients with AHDF, some of the most recent studies have reported conflicting results. Differences in the selection of study population, heterogeneity of the indications for the use of ultrafiltration, disparity in the ultrafiltration protocols, and high variability in the pharmacologic therapies used for the control group could explain some of these contradictory findings. The purpose of the present review is to provide an overview and an update on the mechanisms and clinical effects of ultrafiltration and on currently available evidence supporting its use in ADHF.

UR - http://www.scopus.com/inward/record.url?scp=84926393272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926393272&partnerID=8YFLogxK

U2 - 10.1007/s40256-015-0107-6

DO - 10.1007/s40256-015-0107-6

M3 - Article

C2 - 25650293

AN - SCOPUS:84926393272

VL - 15

SP - 103

EP - 112

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 2

ER -